Newton’s Neurolens® N3 Receives CE Marking Under EU MDR for European Commercialization
Newton’s Neurolens® N3 Receives CE Marking Under EU MDR
Eye care technology company Newton announced that its Neurolens® N3 measurement system has received CE marking under the European Union Medical Device Regulation (EU MDR). Issued by Intertek Medical Notified Body AB, the certification allows the platform to be marketed in approximately 30 European countries. Newton expects to begin introducing Neurolens in its first European markets in 2027, building on its existing presence in the United States and Canada. The N3 system uses eye-tracking technology to measure objective ocular alignment at distance and near, providing data for customized Neurolens Contoured Prism prescriptions. Newton cites a 2024 randomized clinical trial showing an average five-point reduction in HIT-6 scores after four weeks of wear, alongside reports that more than 350,000 patients across North America have been fitted with Neurolens products.
Source:OptikNow · optiknow.ca